J&J chief Alex Gorsky nabbed $25M pay package in year marked by legal controversy

Alex Gorsky
Gorsky is ranked among the highest paid biopharma CEOs with his more than $25 million in pay in 2019. (Johnson & Johnson)

With his company awash in lawsuits over its opioid and baby powder products, Johnson & Johnson helmsman Alex Gorsky has seen his fair share of scrutiny. But that didn't affect his personal bottom line much in 2019.

Gorsky scored $25.37 million in total pay, a nearly $5 million boost over 2018 thanks to an increase in the value of his pension, according to a proxy filing.

In terms of salary, Gorsky's base pay remained flat at $1.65 million in 2019, and his stock and option awards came in slightly lower than in the previous year, but his cash incentive pay rang in at $3.69 million, a slight increase.

The CEO also secured $9.96 million in stock awards and $4.05 million in options, both of them a bit smaller than the awards he snared for 2018. His other compensation totaled $243,000. 

In 2018, Gorsky was paid a total of $20.1 million with no increase in deferred compensation and pension value. 

RELATED: Citing J&J's legal controversies, investor group calls for split of Gorsky's CEO and chairman roles

Suggested Articles

Lupin Pharmaceuticals has shut down an Indian generics plant after 18 workers tested positive for COVID-19, Reuters reported.

Merck KGaA could see billions of dollars in revenue opportunity as it assists certain players with their COVID-19 scale-up, an analyst says. 

The FDA approved Johnson & Johnson's Tremfya as the first IL-23 inhibitor to treat psoriatic arthritis, joining a suite of immunology blockbusters.